AJP - Endo Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (October 6, 2009). doi:10.1152/ajpendo.00272.2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/6/E1339    most recent
ajpendo.00272.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kake, T.
Right arrow Articles by Nakao, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kake, T.
Right arrow Articles by Nakao, K.

RESEARCH ARTICLE

Chronically elevated plasma C-type natriuretic peptide (CNP) level stimulates skeletal growth in transgenic mice.

Takei Kake,1 Hidetomo Kitamura,2,* Yuichiro Adachi,1 Tetsuro Yoshioka,3 Tomoyuki Watanabe,1 Hiroaki Matsushita,1 Toshihito Fujii,3 Eri Kondo,3 Takanori Tachibe,1 Yosuke Kawase,1 Kou-ichi Jishage,1 Akihiro Yasoda,3 Masashi Mukoyama,3 and Kazuwa Nakao3

1Chugai Pharmaceutical Co., ltd. 2Chugai Pharmaceutical Co., Ltd. 3Kyoto University Graduate School of Medicine

Submitted 30 April 2009 ; revised 8 September 2009 ; accepted in final form 27 September 2009

C-type natriuretic peptide (CNP) plays a critical role in endochondral ossification through guanylyl cyclase-B (GC-B), a natriuretic peptide receptor subtype. Cartilage-specific overexpression of CNP enhances skeletal growth and rescues the dwarfism in a transgenic achondroplasia model with constitutive active mutation of fibroblast growth factor receptor 3. For future clinical application, the efficacy of CNP administration on skeletal growth must be evaluated. Due to the high clearance of CNP, maintaining a high concentration is technically difficult. However, to model high blood CNP concentration, we established a liver-targeted CNP-overexpressing transgenic mouse (SAP-CNP tgm). SAP-CNP tgm exhibited skeletal overgrowth in proportion to the blood CNP concentration and revealed phenotypes of systemic stimulation of cartilage bones including limbs, paws, costal bones, spine, and skull. Furthermore, in SAP-CNP tgm, the size of the foramen magnum, the insufficient formation of which results in cervico-medullary compression (CMC) in achondroplasia, also showed significant increase. CNP primarily activates GC-B but under high concentrations it cross-reacts with guanylyl cyclase-A (GC-A), a natriuretic peptide receptor subtype of atrial natriuretic peptides (ANP) and brain natriuretic peptides (BNP). Although activation of GC-A could alter cardiovascular homeostasis leading to hypotension and heart weight reduction, the skeletal overgrowth phenotype in the line of SAP-CNP tgm with mild overexpression of CNP did not accompany decrease of systolic blood pressure or heart weight. These results suggest that CNP administration stimulates skeletal growth without adverse cardiovascular effect, and thus CNP could be a promising remedy targeting achondroplasia.

CNP; transgenic mouse; blood level elevation



* Chugai Pharmaceutical Co., Ltd. kitamurahdt{at}chugai-pharm.co.jp







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.